Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rosuvastatin + ramipril
- Development stage
- Unknown
- Lead developer
- Cardiology Research, University of British Columbia
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination regimen consisting of the HMG-CoA reductase inhibitor rosuvastatin and the angiotensin-converting enzyme (ACE) inhibitor ramipril, currently being investigated in the Phase 4 SAFER-SCAD (Statin and ACE Inhibitor in SCAD) clinical trial. This study, led by Cardiology Research UBC, focuses on women who have previously experienced spontaneous coronary artery dissection (SCAD) and continue to suffer from persistent angina and microvascular coronary dysfunction. Rosuvastatin is a small molecule statin that lowers LDL cholesterol and provides pleiotropic vascular benefits, such as improved endothelial function. Ramipril is a small molecule ACE inhibitor that reduces vasoconstriction and improves microcirculatory resistance. The combination is intended to address the underlying microvascular issues that often persist after the initial arterial dissection has healed.
- Other names
- SAFER-SCAD interventionrosuvastatin and ramipril
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)ACE (Angiotensin Converting Enzyme)
Beyond the preview
Go deeper on rosuvastatin + ramipril.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rosuvastatin + ramipril.